![Quiver Logo](/static/img/logo-icon.png)
![CYTHW logo](https://quiver-logos.s3.us-east-2.amazonaws.com/cythw.png)
Cyclo Therapeutics, Inc. Warrant
Cyclo Therapeutics Inc is a clinical-stage biotechnology firm. The company is engaged in developing cyclodextrin-based products for treating neurodegenerative diseases, particularly Niemann-Pick Type C disease (NPC). The company's lead drug candidate, Trappsol Cyclo, has undergone clinical trials for NPC treatment. Operating in one segment, the company focuses on developing and commercializing cyclodextrin-based treatments for rare diseases. Revenue primarily comes from selling cyclodextrins and related products to pharmaceutical and nutritional industries, with Trappsol HPB and Trappsol Fine Chemical being significant contributors.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view CYTHW Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.
Recent trades of CYTHW by members of U.S. Congress
Recently reported changes by institutional investors
Quarterly net insider trading by CYTHW's directors and management
Government lobbying spending instances
New patents grants
Federal grants, loans, and purchases
Recent insights relating to CYTHW
Recent picks made for CYTHW stock on CNBC
ETFs with the largest estimated holdings in CYTHW
Flights by private jets registered to CYTHW
![Quiver Logo](/static/img/logo-icon.png)